<DOC>
	<DOCNO>NCT02055924</DOCNO>
	<brief_summary>This open label , multicenter , dose escalation , phase Ib study determine recommend dose assess maximum tolerate dose ( MTD ) , safety efficacy ibrutinib combination R-DHAP ( Group A/Abis ) R-DHAOx ( Group B/Bbis ) patient B-cell malignancy . This dose escalation follow exploratory expansion phase 3 group 12 patient ( Group A/Abis , Group B/B bi Group C ) . During Part 1 Dose Escalation , `` 3+3 '' design apply . Three dos ibrutinib ( 280 , 420 560 mg ) examine sequentially cohort Dose Escalation Committee . Dose escalation begin dose level 1 = 420 mg . The dose escalation perform two type association four separate group : - Group A : ibrutinib D1-D21+ R-DHAP - Group B : ibrutinib D1-D21 R-DHAOx - Group Abis : ibrutinib D5-D18+ R-DHAP - Group Bbis : ibrutinib D5-D18 R-DHAOx This dose escalation follow exploratory expansion phase 2 group A/Abis B/Bbis plus third one include mantle cell lymphoma ( MCL ) first line patient : group C. Patients include Group C receive ibrutinib combination R-DHAP R-DHAOx accord choice local investigator time inclusion patient .</brief_summary>
	<brief_title>Bruton 's Tyrosine Kinase ( BTK ) Inhibition B-cell Lymphomas</brief_title>
	<detailed_description>The primary objective study determine recommend dose ibrutinib administer combination R-DHAP ( rituximab + dexamethasone + cytarabine + cisplatin ) R-DHAOx ( rituximab + dexamethasone + cytarabine + oxaliplatin ) patient relapsed refractory B-cell malignancy eligible autologous stem cell transplantation ( ASCT ) assess maximum tolerate dose ( MTD ) observe dose escalation part study . Assessment MTD perform analysis dose-limiting toxicity ( DLTs ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>1 . Patients type relapsed refractory Bcell lymphoma eligible group A , A bi , B B bi ( dose escalation expansion part study ) untreated patient mantle cell lymphoma eligible group C ( expansion part study ) 2 . Each patient ( legally acceptable representative ) must sign informed consent form ( ICF ) indicate understands purpose procedure require study willing participate study 3 . Patients eligible autologous stem cell transplantation ( ASCT ) RDHAP RDHAOx acceptable therapy regard investigator 's opinion 4 . Measurable disease define least one single node tumor lesion &gt; 1.5 cm 5 . Patients receive prior therapy least one two line therapy BCell Lymphoma ( except patient include group C expansion part study ) 6 . Aged 18 year 70 year ( include ) 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 8 . Any following hematology value within 14 day prior inclusion prior first dose study drug : 1 . Absolute neutrophil count ( ANC ) &gt; 1,000 cells/mm3 ( 1.0 x 109/L ) unless bone marrow infiltration lymphoma 2 . Spontaneous Platelets count &gt; 75,000 cells/mm3 ( 75 x 109/L ) within 7 day platelet transfusion ( allow 50 x 109/L due bone marrow infiltration lymphoma ) 9 . Patients assess able receive full dos RDHA ( P/Ox ) 3 cycle 4 cycle patient include group C expansion phase 10 . Life expectancy ≥ 90 day ( 3 month ) 11 . Women childbearing potential* men sexually active must practice highly effective method birth control study 12 month end treatment . Men must agree donate sperm study 12 month end treatment 12 . Women childbearing potential must negative serum beta human chorionic gonadotropin ( βhCG ) urine pregnancy test Screening 1 . Previous treatment BTK inhibitor 2 . Patients progress become refractory treatment phosphoinositide 3kinase ( PI3K ) inhibitors 3 . Inability tolerate 4 course high dose araC / platin compound , especially due underlie comorbidities 4 . History stroke intracranial hemorrhage within 6 month prior first dose study drug 5 . Major surgery , within 4 week prior first dose study drug 6 . Known bleed diathesis 7 . Condition require therapeutic anticoagulation Vitamin K antagonists 8 . Condition require treatment strong cytochrome P450 3A4/5 ( CYP3A4/5 ) inhibitor 9 . Any lifethreatening illness , serious medical condition , laboratory abnormality , organ system dysfunction psychiatric illness , investigator 's opinion , could compromise patient 's safety , interfere absorption metabolism ibrutinib capsule , put study outcome undue risk would prevent patient signing informed consent form 10 . Known central nervous system meningeal involvement lymphoma 11 . Contraindication drug contain regimen 12 . Known history human immunodeficiency virus ( HIV ) 13 . Known active Hepatitis C Virus ( HCV ; RNA polymerase chain reaction ( PCR ) positive ) active Hepatitis B Virus infection ( HBs Ag positive DNA PCRpositive ) uncontrolled active systemic infection require intravenous ( IV ) antibiotic . Patients PCRnegative hepatitis B virus ( HBV ) permit study . 14 . Left ventricular ejection fraction ( LVEF ) &lt; 45 % determine echocardiography multiple uptake gate acquisition ( MUGA ) scan 15 . Clinically significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month prior first dose study drug , Class 3 ( moderate ) Class 4 ( severe ) cardiac disease define New York Heart Association Functional Classification 16 . Any following biochemical value within 14 day prior inclusion prior first dose study drug : 1 . Serum glutamicoxaloacetic transaminase/aspartate aminotransferase ( SGOT/ASAT ) serum glutamicpyruvic transaminase/alanine aminotransferase ( SGPT/ALAT ) &gt; 3.0 x upper limit normal ( ULN ) 2 . Serum total bilirubin &gt; 2.0 mg/dL ( 34 µmol/L ) , except patient hemolytic anemia Gilbert syndrome , 3 . Calculated creatinine clearance &lt; 50 mL /min ( patient DHAOx chemotherapy ) &lt; 70 mL/min ( patient DHAP chemotherapy ) 17 . Patients preexist ≥ Grade 2 neuropathy 18 . Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless patient free disease ≥ 3 year 19 . Use standard experimental anticancer drug therapy within 28 day prior first dose study drug 20 . Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Bruton 's tyrosine kinase ( BTK ) Inhibition B-cell Lymphomas</keyword>
</DOC>